Literature DB >> 7835937

Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus.

L A Bergmeier1, J Walker, L Tao, M Cranage, T Lehner.   

Abstract

Inactivated simian immunodeficiency virus (SIV) grown in a human T-cell line induces protection from infection by the virus in macaques. However, observations that immunization with uninfected human T cells or with SIV-1 prepared in human T cells can also induce protection, has raised the possibility that protective antigens could be of human cellular origin. Sera from animals immunized with fixed infected and uninfected human T cells, as well as from animals immunized with partially purified cell-free SIV have been examined for their ability to bind to human and macaque peripheral blood mononuclear cells (PBMC) and to-components present in fetal calf serum (FCS) in which the cells were grown. Analysis by flow cytometry suggests that antibodies to human cell surface antigens can be elicited with both inactivated SIV grown in human T cells and by uninfected T cells. There was a significant association between the presence of anti-cell antibodies and protection from infection. However, anti-cell surface antibodies were not detected with macaque mononuclear cells by flow cytometry or by immunoprecipitation, unless these cells were first treated with FCS or activated by a mitogen. Immunoprecipitation of resting human PBMC with sera from immunized animals suggests the presence of antibodies to class I heavy and light chains [beta 2-microglobulin (beta 2 m)] and to bovine beta 2m, which may originate in FCS used to grow the cell line. Antibodies to CD4 were also found in sera from animals immunized with SIV grown in human T cells. We suggest that human cellular components augmented by FCS elicit anti-class I heavy chain, beta 2m, CD4 and FCS antibodies which may be responsible for protection against SIV infection in macaques.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7835937      PMCID: PMC1414951     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  22 in total

1.  Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus.

Authors:  M D Daniel; N L Letvin; P K Sehgal; G Hunsmann; D K Schmidt; N W King; R C Desrosiers
Journal:  J Gen Virol       Date:  1987-12       Impact factor: 3.891

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III.

Authors:  L E Henderson; R Sowder; T D Copeland; S Oroszlan; L O Arthur; W G Robey; P J Fischinger
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

4.  Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus.

Authors:  M P Cranage; N Polyanskaya; B McBride; N Cook; L A Ashworth; M Dennis; A Baskerville; P J Greenaway; T Corcoran; P Kitchin
Journal:  AIDS Res Hum Retroviruses       Date:  1993-01       Impact factor: 2.205

5.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

6.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

7.  Beta 2-microglobulin from serum associates with MHC class I antigens on the surface of cultured cells.

Authors:  C Bernabeu; M van de Rijn; P G Lerch; C P Terhorst
Journal:  Nature       Date:  1984 Apr 12-18       Impact factor: 49.962

8.  Inoculation of baboons and macaques with simian immunodeficiency virus/Mne, a primate lentivirus closely related to human immunodeficiency virus type 2.

Authors:  R E Benveniste; W R Morton; E A Clark; C C Tsai; H D Ochs; J M Ward; L Kuller; W B Knott; R W Hill; M J Gale
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

9.  Necropsy findings in rhesus monkeys experimentally infected with cultured simian immunodeficiency virus (SIV)/delta.

Authors:  G B Baskin; M Murphey-Corb; E A Watson; L N Martin
Journal:  Vet Pathol       Date:  1988-11       Impact factor: 2.221

10.  Phenotypic expression of Vicia villosa binding T cell subsets, as markers of contrasuppressor cells in systemic lupus erythematosus.

Authors:  F Fortune; T Lehner
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

View more
  6 in total

1.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies.

Authors:  S Giannecchini; D Del Mauro; D Matteucci; M Bendinelli
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

2.  Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates.

Authors:  Lukas Flatz; Cheng Cheng; Lingshu Wang; Kathryn E Foulds; Sung-Youl Ko; Wing-Pui Kong; Rahul Roychoudhuri; Wei Shi; Saran Bao; John-Paul Todd; Mohammed Asmal; Ling Shen; Mitzi Donaldson; Stephen D Schmidt; Jason G D Gall; Daniel D Pinschewer; Norman L Letvin; Srinivas Rao; John R Mascola; Mario Roederer; Gary J Nabel
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques.

Authors:  Y Wang; L Tao; E Mitchell; W M Bogers; C Doyle; C A Bravery; L A Bergmeier; C G Kelly; J L Heeney; T Lehner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

4.  Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; L Zaccaro; P Bandecchi; F Tozzini; M Bendinelli
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

5.  Cytoskeletal proteins bound to heat-shock protein 70 may elicit resistance to simian immunodeficiency virus infection of CD4(+) T cells.

Authors:  Lesley A Bergmeier; Kaboutar Babaahmady; Jeffrey Pido-Lopez; Kate J Heesom; Charles G Kelly; Thomas Lehner
Journal:  Immunology       Date:  2009-11-25       Impact factor: 7.397

6.  Greater ethnic diversity correlates with lower HIV prevalence in Africa: justification for an alloimmunity vaccine.

Authors:  Christopher Zamani; Jared D Elzey; James Ek Hildreth
Journal:  HIV AIDS (Auckl)       Date:  2013-04-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.